Role of Two Single Nucleotide Polymorphisms in Secreted Frizzled Related Protein 1 and Bladder Cancer Risk

Overview

Journal Int J Clin Exp Pathol

Specialty Pathology

Date 2013 Oct 18

PMID 24133576

Citations 10

Authors

Anja Rogler

Sabine Hoja

Eileen Socher

Elke Nolte

Sven Wach

Wolf Wieland

Ferdinand Hofstadter

Peter J Goebell

Bernd Wullich

Arndt Hartmann

Robert Stoehr

Affiliations

Soon will be listed here.

Abstract

In this study, we determined the genotype distribution of two single nucleotide polymorphisms (SNPs) in secreted frizzled related protein 1 (SFRP1), rs3242 and rs921142, in a Caucasian bladder cancer case-control study. Allelic variants of the SNPs were determined using restriction fragment length polymorphism (RFLP) analysis and partly verified by sequencing analysis. Overall, DNA from 188 consecutive and 215 early-onset bladder cancer patients (≤45 years) as well as from 332 controls was investigated. Potential microRNA binding sites were determined for rs3242, and microRNA expression was analysed in cell lines and tumour specimens. We observed a remarkable distribution difference in rs3242 between bladder cancer patients and healthy controls (p=0.05). Additionally, we found a significant difference in genotype distribution (p=0.032), resulting from the difference of early-onset patients and the control group (p=0.007). The risk allele T showed increased frequency in the early-onset patient group (p=0.002). Genotype-dependent differences of microRNA binding capacity were predicted in SFRP1 mRNA for two microRNAs. Hsa-miR-3646 showed strong expression in cell lines and tumour tissue, whereas hsa-miR-603 exhibited weak expression. The rs921142 SNP showed no significant association with bladder cancer risk. This is the first study to describe an association of the SFRP1 SNP rs3242 and bladder cancer risk as well as the influence of rs3242 on genotype-dependent microRNA capacity on SFRP1 mRNA. The onset of bladder seems to be associated with the increased occurrence of the T-allele in rs3242.

Citing Articles

SFRP2 mediates Epstein-Barr virus and bladder cancer risk: a Mendelian randomization study and colocalization analysis.

Li J, Yang B, Guo L, Huang W, Hu Q, Yan H Sci Rep. 2025; 15(1):7118.

PMID: 40016549 PMC: 11868617. DOI: 10.1038/s41598-025-91594-9.

MicroRNA miR-3646 promotes malignancy of lung adenocarcinoma cells by suppressing sorbin and SH3 domain-containing protein 1 via the c-Jun NH2-terminal kinase signaling pathway.

Wang C, Cheng B Bioengineered. 2022; 13(3):4869-4884.

PMID: 35196185 PMC: 8973682. DOI: 10.1080/21655979.2022.2036889.

Harnessing low-density lipoprotein receptor protein 6 (LRP6) genetic variation and Wnt signaling for innovative diagnostics in complex diseases.

Wang Z, Luo J, Xu L, Zhou H, Zhang W Pharmacogenomics J. 2017; 18(3):351-358.

PMID: 28696417 DOI: 10.1038/tpj.2017.28.

Bioinformatics analysis of dysregulated microRNAs in the nipple discharge of patients with breast cancer.

Zhang K, Wang Y, Ma R Oncol Lett. 2017; 13(5):3100-3108.

PMID: 28521415 PMC: 5431374. DOI: 10.3892/ol.2017.5801.

Bladder cancer: Micro RNAs as biomolecules for prognostication and surveillance.

Mitash N, Tiwari S, Agnihotri S, Mandhani A Indian J Urol. 2017; 33(2):127-133.

PMID: 28469300 PMC: 5396400. DOI: 10.4103/0970-1591.203412.

References

Pignot G, Vieillefond A, Vacher S, Zerbib M, Debre B, Lidereau R . Hedgehog pathway activation in human transitional cell carcinoma of the bladder. Br J Cancer. 2012; 106(6):1177-86. PMC: 3304423. DOI: 10.1038/bjc.2012.55. View

Konigshoff M, Balsara N, Pfaff E, Kramer M, Chrobak I, Seeger W . Functional Wnt signaling is increased in idiopathic pulmonary fibrosis. PLoS One. 2008; 3(5):e2142. PMC: 2374879. DOI: 10.1371/journal.pone.0002142. View

Moon R, Kohn A, De Ferrari G, Kaykas A . WNT and beta-catenin signalling: diseases and therapies. Nat Rev Genet. 2004; 5(9):691-701. DOI: 10.1038/nrg1427. View

Wasielewski M, Nagel J, Brekelmans C, Klijn J, van den Ouweland A, Meijers-Heijboer H . MDM2 SNP309 accelerates familial breast carcinogenesis independently of estrogen signaling. Breast Cancer Res Treat. 2006; 104(2):153-7. DOI: 10.1007/s10549-006-9407-5. View

Sanchez-Carbayo M, Socci N, Kirchoff T, Erill N, Offit K, Bochner B . A polymorphism in HDM2 (SNP309) associates with early onset in superficial tumors, TP53 mutations, and poor outcome in invasive bladder cancer. Clin Cancer Res. 2007; 13(11):3215-20. DOI: 10.1158/1078-0432.CCR-07-0013. View

Caldwell G, Jones C, Gensberg K, Jan S, Hardy R, Byrd P . The Wnt antagonist sFRP1 in colorectal tumorigenesis. Cancer Res. 2004; 64(3):883-8. DOI: 10.1158/0008-5472.can-03-1346. View

Nakashima M, Kondo S, Shimizu Y, Wakisaka N, Murono S, Furukawa M . Impact of MDM2 single nucleotide polymorphism on tumor onset in head and neck squamous cell carcinoma. Acta Otolaryngol. 2008; 128(7):808-13. DOI: 10.1080/00016480701724904. View

Dahl E, Wiesmann F, Woenckhaus M, Stoehr R, Wild P, Veeck J . Frequent loss of SFRP1 expression in multiple human solid tumours: association with aberrant promoter methylation in renal cell carcinoma. Oncogene. 2007; 26(38):5680-91. DOI: 10.1038/sj.onc.1210345. View

Klaus A, Birchmeier W . Wnt signalling and its impact on development and cancer. Nat Rev Cancer. 2008; 8(5):387-98. DOI: 10.1038/nrc2389. View

10.

Gumz M, Zou H, Kreinest P, Childs A, Belmonte L, LeGrand S . Secreted frizzled-related protein 1 loss contributes to tumor phenotype of clear cell renal cell carcinoma. Clin Cancer Res. 2007; 13(16):4740-9. DOI: 10.1158/1078-0432.CCR-07-0143. View

11.

Stoehr R, Wissmann C, Suzuki H, Knuechel R, Krieg R, Klopocki E . Deletions of chromosome 8p and loss of sFRP1 expression are progression markers of papillary bladder cancer. Lab Invest. 2004; 84(4):465-78. DOI: 10.1038/labinvest.3700068. View

12.

Veeck J, Niederacher D, An H, Klopocki E, Wiesmann F, Betz B . Aberrant methylation of the Wnt antagonist SFRP1 in breast cancer is associated with unfavourable prognosis. Oncogene. 2006; 25(24):3479-88. DOI: 10.1038/sj.onc.1209386. View

13.

Wei W, Chua M, Grepper S, So S . Blockade of Wnt-1 signaling leads to anti-tumor effects in hepatocellular carcinoma cells. Mol Cancer. 2009; 8:76. PMC: 2759906. DOI: 10.1186/1476-4598-8-76. View

14.

Ohnaka K, Yamamoto K, Nakamura K, Adachi M, Kawate H, Kono S . Association of single nucleotide polymorphisms in secreted frizzled-related protein 1 gene with bone mineral density in Japanese women. Geriatr Gerontol Int. 2009; 9(3):304-9. DOI: 10.1111/j.1447-0594.2009.00540.x. View

15.

Huang S, Chen I, Liao C, Wang H, Liou S, Hsieh L . Combined effects of MDM2 SNP 309 and p53 mutation on oral squamous cell carcinomas associated with areca quid chewing. Oral Oncol. 2008; 45(1):16-22. DOI: 10.1016/j.oraloncology.2008.03.006. View

16.

Rieger K, Little A, Swart J, Kastrinakis W, Fitzgerald J, Hess D . Human bladder carcinoma cell lines as indicators of oncogenic change relevant to urothelial neoplastic progression. Br J Cancer. 1995; 72(3):683-90. PMC: 2033904. DOI: 10.1038/bjc.1995.394. View

17.

Swinney R, Hsu S, Hirschman B, Chen T, Tomlinson G . MDM2 promoter variation and age of diagnosis of acute lymphoblastic leukemia. Leukemia. 2005; 19(11):1996-8. DOI: 10.1038/sj.leu.2403941. View

18.

Bond G, Hu W, Bond E, Robins H, Lutzker S, Arva N . A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell. 2004; 119(5):591-602. DOI: 10.1016/j.cell.2004.11.022. View

19.

Neuhausen A, Florl A, Grimm M, Schulz W . DNA methylation alterations in urothelial carcinoma. Cancer Biol Ther. 2006; 5(8):993-1001. DOI: 10.4161/cbt.5.8.2885. View

20.

Bartel F, Jung J, Bohnke A, Gradhand E, Zeng K, Thomssen C . Both germ line and somatic genetics of the p53 pathway affect ovarian cancer incidence and survival. Clin Cancer Res. 2008; 14(1):89-96. DOI: 10.1158/1078-0432.CCR-07-1192. View